SNY
NASDAQ · Healthcare
Sanofi
$42.71
+0.23 (+0.54%)
SNY News14 articles
Novartis Surges on MS Drug Data, $3B Peak Sales Forecast
Novartis (NVS) shares jumped 5.6% after Phase III trials for remibrutinib in multiple sclerosis met primary endpoints, with BofA projecting $3B peak sales. Full data due Oct 21-23.
Novartis Jumps 6% on Remibrutinib Data as Patent Cliff Looms
Novartis ADRs jumped 6% after remibrutinib met Phase III endpoints in multiple sclerosis, easing concerns about patent expirations. Stock hit $161.22.
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
Attovia Therapeutics Files IPO to Challenge Dupixent and Nemluvio
Attovia Therapeutics has filed for an IPO to raise capital for developing rival treatments to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Regeneron Q1 Results Top Estimates, Eylea Challenges Loom
Regeneron reported strong Q1 results with revenue up 19% and earnings above estimates, but Eylea sales declined and an FDA delay on a new syringe manufacturer weighs on shares.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.